Latest News and Updates | Cantargia

* (R) = Regulatory press releases

May 26, 2022

(R) Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor

May 23, 2022

(R) Annual General Meeting in Cantargia AB (publ)

May 23, 2022

(R) Cantargia publishes interim report for first quarter 2022

May 22, 2022

(R) Cantargia reports positive preclinical effects in atherosclerosis demonstrating potential of CAN10 in cardiovascular disease

May 17, 2022

Invitation to presentation of Cantargia’s report for the first quarter of 2022 on May 23 at 10.00 a.m. CET

Apr 29, 2022

(R) Cantargia publishes annual report for the financial year 2021

Apr 27, 2022

(R) Cantargia to present new clinical data on lead IL1RAP antibody nadunolimab over three sessions at ASCO 2022

Apr 22, 2022

(R) Notice of annual general meeting in Cantargia AB (publ)

Mar 10, 2022

(R) Correction: Cantargia strengthens executive management in preparation for late-stage clinical development

Mar 10, 2022

Cantargia strengthens executive management in preparation for late-stage clinical development

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye